Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.61 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | AKT1 | P31749 | 4/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17452770 | 0.90 | ROCK2 (0.59) | ROCK2ROCK1NOTUMAKT1PARP1 | |
| SCHEMBL19902337 | 0.77 | NPC1 (0.57) | ROCK2ROCK1 | |
| SCHEMBL15897948 | 0.76 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL17437860 | 0.75 | ROCK2 (0.53) | ROCK2ROCK1NOTUMAKT1 | |
| SCHEMBL19902546 | 0.73 | ROCK2 (0.61) | ROCK2ROCK1 | |
| SCHEMBL19902689 | 0.72 | ROCK2 (0.46) | ROCK2ROCK1 | |
| SCHEMBL20229844 | 0.71 | ROCK1 (0.45) | ROCK2ROCK1 | |
| SCHEMBL6543320 | 0.70 | NOTUM (0.57) | ROCK2ROCK1NOTUMAKT1 | |
| SCHEMBL19902690 | 0.69 | SMN1; SMN2 (0.44) | ROCK2ROCK1PARP1 | |
| SCHEMBL3988046 | 0.69 | ROCK2 (0.50) | ROCK2ROCK1NOTUMAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | ROCK2 3/4885ROCK1 1/4885NOTUM 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.